| Name | Title | Contact Details |
|---|
BABY BLANKET SUNCARE is a Rehoboth, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Roche Diagnostics, our focus is to improve the lives of patients, from research to lab tests to personalized healthcare; we touch the entire spectrum of diagnostics users. Roche Diagnostics is a member of the Roche Group, which is headquartered in Basel, Switzerland. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world`s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche`s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. Roche has over 90,000 employees worldwide and invested over 9 billion Swiss francs in R&D. Roche Diagnostics` North American headquarters, located in Indianapolis, has about 4,200 employees and is home to U.S. research and development, laboratory, manufacturing, distribution, information technology and administrative operations.
Maxim Healthcare Services is a healthcare staffing agency that provides recruitment, training, and management of a diverse healthcare workforce for their clients.
Professional Medical Management Service is a Maspeth, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.